Terms: = Gastric cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
10 results:
1. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
2. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in gastric cancer.
Xiang R; Ge Y; Song W; Ren J; Kong C; Fu T
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680930
[TBL] [Abstract] [Full Text] [Related]
3. [Clinicopathological characteristics and prognostic analysis of 92 cases with primary gastrointestinal diffuse large B-cell lymphoma].
Feng J; Wan W; Wan W; Wang J; Jing H; Wang J; Zhao W; Liu Y; Ke X
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):288-94. PubMed ID: 24759013
[TBL] [Abstract] [Full Text] [Related]
4. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Huang H; Han Y; Gao J; Feng J; Zhu L; Qu L; Shen L; Shou C
Med Oncol; 2013 Dec; 30(4):748. PubMed ID: 24135868
[TBL] [Abstract] [Full Text] [Related]
5. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract] [Full Text] [Related]
6. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.
Iqbal S; Goldman B; Fenoglio-Preiser CM; Lenz HJ; Zhang W; Danenberg KD; Shibata SI; Blanke CD
Ann Oncol; 2011 Dec; 22(12):2610-2615. PubMed ID: 21415234
[TBL] [Abstract] [Full Text] [Related]
7. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Di Fabio F; Pinto C; Rojas Llimpe FL; Fanti S; Castellucci P; Longobardi C; Mutri V; Funaioli C; Sperandi F; Giaquinta S; Martoni AA
Gastric Cancer; 2007; 10(4):221-7. PubMed ID: 18095077
[TBL] [Abstract] [Full Text] [Related]
8. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract] [Full Text] [Related]
9. [A case of partial response in liver metastatic lesion from gastric endocrine cell carcinoma treated with TS-1].
Hanada N; Inoue K; Osako T; Kuriwaki K; Shimajiri S; Mochinaga M
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1143-6. PubMed ID: 16912536
[TBL] [Abstract] [Full Text] [Related]
10. [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Mikami Y; Tsukuda M; Kawai S; Kagesato Y; Tanigaki Y; Horiuchi C; Mochimatsu I
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1473-7. PubMed ID: 14584280
[TBL] [Abstract] [Full Text] [Related]
